Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
Metabolic dysfunction‐associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle‐aged and older US population.
Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
- المؤلفون: Yang, Sheng; Cheng, Jiawen; Zhang, Rui; Sun, Huiwen; Zhang, Hui; Lyu, Sali; Duan, Weiwei
- المصدر:
Hepatology Research; Feb2022, Vol. 52 Issue 2, p176-186, 11p
- الموضوع:
- معلومة اضافية
- الموضوع:
- نبذة مختصرة :
Aim: The global burden of chronic liver disease is substantial. Limited studies have reported the prevalence of metabolic dysfunction‐associated fatty liver disease (MAFLD) and liver fibrosis among middle‐aged and older people. Therefore, we aimed to determine the nationwide prevalence of and associated factors for MAFLD and fibrosis in adults aged 45–79 years from the United States. Methods: This cross‐sectional study utilized data from the 2017–2018 cycle of the National Health and Nutrition Examination Survey conducted with a nationally representative sample of the civilian, noninstitutionalized US population. Hepatic steatosis and fibrosis were assessed by transient elastography with controlled attenuation parameter and liver stiffness measurement, respectively. Results: A total of 1186 eligible participants aged 45–79 years were finally included in the analyses. The estimated prevalence of MAFLD, significant fibrosis (F ≥ F2), and advanced fibrosis (F ≥ F3) was 48.6% (95% confidence interval [CI], 43.1%–54.0%), 9.5% (95% CI, 6.8%–12.7%), and 6.7% (95% CI, 4.1%–10.1%), respectively. Multivariable logistic regression revealed an increased MAFLD predisposition in subjects with metabolic disorders including overweight/obesity, abdominal obesity, hypertension, and diabetes mellitus. Moreover, the presence of depression was an independent and strong predictor of MAFLD risk (odds ratio = 3.23; 95% CI, 1.37–7.11). Elevated liver enzymes, hypertension, diabetes mellitus, hepatitis virus infection, and steatosis were associated with a high risk of significant fibrosis. Conclusions: Newly defined MAFLD is highly prevalent in the US middle‐aged and older population. Approximately 1 in 10 people has significant liver fibrosis. In addition to metabolic disorders, the presence of depression potentially increases the risk of MAFLD. [ABSTRACT FROM AUTHOR]
- نبذة مختصرة :
Copyright of Hepatology Research is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
No Comments.